Perform Another (Advanced) Search

1.  Study Posting (783) Trial #161601, Parkinson's Disease, Lexington, KY
...783) Trial #161601, Parkinson's Disease, Lexington, KY Trial Information A Phase 4 Study of Rasagiline or Placebo as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease. Patients will receive 1mg rasagiline or matching placebo daily. Study will last approximately 18 weeks, with 4 study visits. Inclusion ...
View Page

2.  CenterWatch: Clinical Trials in Category (117) Parkinson's Disease
...s Disease? Kentucky Lexington : Associates in Neurology, P.S.C. A Phase 4 Study of Rasagiline or Placebo as an Add on Therapy to Stable Dose of Dopamine Agonists in the ...
View Page

3.  CenterWatch: New Medical Therapies in Disease Category (117), Parkinson's Disease
...and H. Lundbeck have reported positive data from their phase III “PRESTO” study of Agilect (rasagiline) , in the treatment of Parkinson’s disease (PD). Trial results indicated that the addition of ...
...results. September 8, 2003 Teva Neuroscience reported positive results from a post-marketing trial investigating rasagiline , a (MAO-B) inhibitor for the treatment of Parkinson’s disease. Results showed that Rasagiline ...
View Page

4.  CenterWatch Clinical Research Profile (783) Trial #343, Associates in Neurology, P.S.C., Lexington, KY
...evaluating treatment with extended release Oxcarbazepine versus placebo for epilepsy. • A Phase 4 Study of Rasagiline or Placebo as an Add on Therapy to Stable Dose of Dopamine Agonists in the ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (189), Insomnia
...and H. Lundbeck have reported positive data from their phase III “PRESTO” study of Agilect (rasagiline) , in the treatment of Parkinson’s disease (PD). Trial results indicated that the addition of ...
View Page